COVID19 vaccine for kids/ photo MDA
A new Covid-19 vaccine cold Corbevax could just be an answer to the world’s prayers. Developed by scientists at from the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, the new Covid-19 vaccine is patent free and so would be really cheap to acquire for the billions of people all over the world.
The new vaccine has already been approved in India for emergency use for Covid-19.
So, how does this new Coronavirus vaccination work? Dubbed “The World’s COVID-19 Vaccine”, Corbevax uses a traditional recombinant protein-based technology that will enable its production at large scales making it widely accessible to inoculate the global population. The initial construct and production process of the vaccine antigen was developed at Texas Children’s Hospital CVD, led by Co-directors Drs. Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Clinical trials involving more than 3000 subjects found Corbevax to be safe, well tolerated and immunogenic. As for the Delta Starin, the new Covid-19 vaccination was found to 80 percent effective for the prevention of symptomatic infections based on published studies.
–
Corbevax, a COVID-19 vaccine created at #TexasChildrens and @bcmhouston could soon be ready for distribution in India. Corbevax is currently being developed in India, with the goal of vaccinating other low- and middle-income nations across the globe. https://t.co/1E51W9CpuS
— Texas Children’s (@TexasChildrens) December 10, 2021
“Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world,” said Dr. Maria Elena Bottazzi, Professor and Associate Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children’s Hospital Center for Vaccine Development. “Our decade-long studies advancing coronavirus vaccine prototypes has led to the creation of this vaccine, which will fill the access gap created by the more expensive, newer vaccine technologies and that today are still not able to be quickly scaled for global production.”
“This announcement is an important first step in vaccinating the world and halting the pandemic. Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant,” said Dr. Peter Hotez, Professor and Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children’s Hospital Center for Vaccine Development. “Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”
